The effect of recanalization of a chronic total coronary occlusion on P-wave dispersion

Aydın Rodi Tosu1, Muhsin Kalyoncuoğlu1, Halil İbrahim Biter1, Sinem Çakal1, Beytullah Çakal2, Tufan Çınar1, Erdal Belen1, Mehmet Mustafa Can1

1Health Sciences University, Haseki Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
2Istanbul Medipol University, Faculty of Medicine, Department of Cardiology, Istanbul, Turkey
3Health Sciences University, Sultan II. Abdülhamid Han Training and Research Hospital, Department of Cardiology, Istanbul, Turkey

Abstract

Introduction: P-wave dispersion (PWD) obtained from the standard 12-lead electrocardiography (ECG) is considered to reflect the homogeneity of the atrial electrical activity. The aim of this investigation was to evaluate the effect of percutaneous chronic total occlusion (CTO) revascularization on the parameters of P wave duration and PWD on ECG in cases before and after procedure at 12th months.

Methods: We analyzed 90 consecutive CTO cases who were on sinus rhythm and underwent percutaneous coronary intervention (PCI). P-wave maximum (Pmax) and P-wave minimum (Pmin), P-wave time, and PWD were determined before and twelve months after the CTO intervention. The study population was categorized into two groups as successful and unsuccessful CTO PCI groups.

Results: The CTO PCI was successful in 71% of cases (n = 64) and it was unsuccessful in 29% of cases (n = 26). Both groups, except for age and hypertension, were similar in terms of demographic and clinical aspects. CRP levels were significantly elevated in the unsuccessful CTO PCI group. Pre-PCI ECG parameters showed no significant difference. Irrespective of the target vessel revascularization, we observed that PWD and Pmax values were significantly lower in the 12th months follow-up. In all Rentrop classes, PWD values were significantly decreased at 12th months follow-up in comparison to the pre-CTO PCI values.

Conclusion: This study has determined that PWD and Pmax, which are both risk factors for atrial arrhythmias, are significantly reduced within 12th months after successful CTO PCI regardless of the target vessel.

Introduction

In patients with paroxysmal atrial fibrillation (AF), the duration of the P-wave appears to be essential to assess the inhomogeneity of electrical atrial activity. Additionally, P-wave dispersion (PWD) obtained from the standard 12-lead electrocardiography (ECG) is considered to reflect the homogeneity of the atrial electrical activity, and it appears to be quite promising in the perspective of AF prediction.1 A prolonged duration of PWD has been reported to increase the risk of developing AF in cases without underlying heart disease.2 AF is the commonly observed cardiac arrhythmia, with a 25% lifetime risk along with associated complications in the population, including heart failure, stroke, and death.3 In developed countries, hypertension and coronary artery disease (CAD) are the main clinical diagnoses associated with AF. CAD rarely causes direct atrial ischemia and AF. More frequently, CAD causes severe ventricular ischemia leading an increase in intra-atrial pressure and AF.4

Chronic total occlusion (CTO) is commonly observed in daily practice, and it is detected roughly 20% of all cases undergoing coronary angiography (CAG).3 The frequency of CTO in cases with known CAD is between 30% and 50%.6 Some studies have investigated whether CTO percutaneous coronary intervention (PCI) can improve ventricular repolarization homogeneity. For example, Erdogan et al showed that after CTO PCI, effective revascularization may result in improved regional heterogeneity of myocardial repolarization, as demonstrated by lower QT dispersion (QTd).7 In addition, there is existing data on P-wave maximum time (Pmax) and PWD showing an association with myocardial ischemia.8 However, the data is lacking on the outcome of CTO PCI revascularization on Pmax and PWD parameters in the ECG. Therefore, we aimed to appraise the effect of CTO PCI revascularization on atrial conduction abnormalities, including Pmax and PWD, in patients before and after procedure at 12 months.
Materials and Methods

Study population

This study was planned as a retrospective and cohort study, and it was carried out conforming to the principles outlined in the Declaration of Helsinki. Initially, 108 consecutive CTO cases who underwent PCI at Istanbul Haseki Training and Research hospital between January 2014 and January 2020 were analyzed. Patients who had AF, atrial flutter and pre-excitation and those cases with permanent pacemakers, severe electrolyte imbalance before and after CTO procedure, undergoing hemodialysis, having congenital heart disease were not excluded. Additionally, patients whose ECG records were unsuitable for analyses and those with missed follow-up were excluded from the study group (n = 18). The hospital’s electronic medical database systems provided demographic, clinical, echocardiographic and biochemical data for all patients. All cardiovascular risk factors were noted. In the present investigation, each case was treated with acetylsalicylic acid, beta blocker, angiotensinogen converting enzyme inhibitors/angiotensinogen receptor blockers, and statin therapy unless contraindicated. Blood samples were taken from the antecubital vein at our hospital within 24 hours of admission. An autoanalyzer was used to quantify total white blood cell (WBCs) count, hemoglobin, platelets, neutrophils, and lymphocytes. An automated chemistry analyzer was used to assess the plasma levels of fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and creatinine in all patients. Roche Diagnostics Cobas 8000 c502 analyzer was used to test C-reactive protein (CRP) levels (Roche Holding AG, Basel, Switzerland).

CTO procedure

A CTO lesion, under the guidance of the Euro CTO Club, was defined as a completely occluded lesion for more than 3 months. CTO lesions were also classified according to coronary collateral flow using the Rentrop classification. Rentrop classification defines collateral circulation between 0 and 3. Rentrop 0: no visible collateral flow, Rentrop 1: filling the lateral branches of the occluded artery, Rentrop 2: partial filling of the epicardial coronary vessel, Rentrop 3: complete collateral filling of the epicardial coronary artery. Recanalization of the CTO indication was confirmed with the presence of angina pectoris in the occluded artery area and/or myocardium (viable or ischemic) with diagnostic tools. After stent deployment, a successful CTO PCI was defined as restoring grade 3 Thrombolysis in Myocardial Infarction (TIMI) flow with less than 20% remaining stenosis in the CTO segment.

ECG analysis

A conventional 12-lead ECG (Schiller Cardiovit AT-102-G2 machine) with 25 mV recording was acquired after a 10-minute rest in the supine position for each case included in the study. In all cases, baseline ECG and 12th months ECG were obtained. The P wave was estimated from the first evidence of upward departure from the baseline until the point of return to the baseline. The difference between the P-wave maximum time (P\text{max}), and P-wave minimum time (P\text{min}) observed in any of the 12 leads was termed as PWD (Figure 1). For each lead, P-wave duration was calculated manually on a high-resolution computer screen by two investigators who were blinded to the clinical details of the cases. All P-wave parameters were measured by two cardiologists separately before and one year after the procedure, and the mean of these two values were accepted as the PWD, P\text{max}, and P\text{min}. Intra-and inter-observer coefficients of variation were 3% and 4% for P wave duration, and 4% and 5% for PWD, respectively.

Statistical analysis

The statistical analysis was performed using SPSS version 15.0 (IBM Corporation, USA) for Windows (Microsoft Inc, USA). Mean, standard deviation (SD), median, and [interquartile range (IQR)] or frequencies were used to convey descriptive data. The Mann-Whitney U test or the independent samples Student’s test were used to compare group means. The Pearson's 2 test was used to compare categorical variables. Statistical significance was defined as a P < 0.05.

Results

In overall, 90 consecutive CTO cases were analyzed. The study cohort was categorized into two groups as successful CTO PCI (n = 64; 71%) and unsuccessful CTO PCI groups (n = 26; 29%). Pre-procedural demographic, clinical, laboratory, angiographic data are displayed in Table 1. Both groups, except for age and hypertension, were similar in terms of demographic and clinical aspects. Additionally, successful revascularization of CTO vessel was significantly lower in cases with previous coronary aorto bypass grafting. In regard to laboratory data, CRP levels were significantly elevated and hemoglobin levels were significantly reduced in the failed PCI group. CTO segment was mostly located in the right coronary artery (RCA; 55.6%). Afterwards, the left anterior descending artery (LAD) and circumflex...
artery (CX) were target arteries in 23.3% and 21.1% of the patients, respectively.

Pre-CTO PCI P-wave parameters and post-CTO PCI P-wave parameters at 12th months are summarized in Table 2. At baseline, P-wave parameters, including P\textsuperscript{max}, P\textsuperscript{min} and PWD, were similar between two groups. P\textsuperscript{max} values at 12th months after successful CTO PCI were statistically lower than the baseline (114.8 ± 3.3 ms vs 108.8 ± 3.3 ms, P < 0.001, respectively). P\textsuperscript{min} values at 12th months were statistically higher than the baseline (56 ± 3.3 ms vs 57.2 ± 4.5 ms, P = 0.002, respectively). PWD was significantly lower than the baseline at 12th months (58.7 ± 6.1 ms vs 51.4 ± 6.3, P < 0.001, respectively). In contrast to that, in the failed CTO PCI group, no significant changes were detected at 12th months in terms of P\textsuperscript{max}, P\textsuperscript{min}, and PWD values.

When the successful PCI group was evaluated based on the Rentrop classification, it was noted that they were mostly Rentrop class 3 patients (45.3%). Compared to pre-CTO PCI values in all Rentrop classes at the 12th months, PWD values were most reduced in Rentrop class 3 patients (Table 3).

| Table 1. Demographic, clinical, laboratory and electrocardiographic parameters of the study cohort |
|---------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| All population (n = 90)                           | Successful CTO PCI (n = 64) | Unsuccessful CTO PCI (n = 26) | P value |
| Male gender, n %                                  | 57 (63.3)        | 36 (56.3)        | 21 (80.8)       | 0.03 |
| Age, years                                       | 56 ± 9.2         | 53.8 ± 8.6       | 61.6 ± 8.4      | <0.01 |
| Hypertension, n %                                | 54 (60)          | 32 (50)          | 22 (84.6)       | <0.01 |
| Diabetes mellitus, n %                           | 57 (64)          | 39 (61.9)        | 18 (69.2)       | 0.51 |
| Smoking, n %                                     | 38 (42.2)        | 26 (40.6)        | 12 (46.2)       | 0.63 |
| Previous MI, n %                                 | 34 (37.8)        | 23 (35.9)        | 11 (42.3)       | 0.57 |
| Previous CABG, n %                               | 18 (20)          | 9 (14.1)         | 3 (34.6)        | 0.03 |
| Previous CVA, n %                                | 2 (2.2)          | 2 (3.1)          | 0 (0)           | 0.36 |
| LVEF, %                                          | 55.7 ± 3.9       | 55.3 ± 3.9       | 56.5 ± 3.9      | 0.18 |
| Creatinine, mg/dl                                | 0.8 [0.8-1.0]    | 0.8 [0.8-0.9]    | 0.8 [0.8-1.0]   | 0.53 |
| TC, mg/dl                                        | 204 ± 36.7       | 208 ± 39.1       | 193 ± 28        | 0.08 |
| LDL-C, mg/dl                                     | 134.6 ± 32.9     | 143.8 ± 35.2     | 135.9 ± 26.3    | 0.30 |
| HDL-C, mg/dl                                     | 41.7 ± 6.6       | 41.6 ± 7.0       | 41.9 ± 5.7      | 0.84 |
| CRP, mg/dl                                       | 4.9 [1.5-12]     | 4.4 [1.3-8.3]    | 12.8 [1.7-14.0] | <0.01 |
| Uric acid, mg/dl                                 | 5.4 ± 1.8        | 5.5 ± 1.9        | 5.2 ± 1.4       | 0.57 |
| Hemoglobin g/dl                                  | 13.8 ± 2.1       | 14.2 ± 1.7       | 12.7 ± 2.8      | <0.01 |
| Neutrophil, µx10\textsuperscript{3}/µL           | 4.9 ± 1.3        | 5.1 ± 1.4        | 4.5 ± 1.2       | 0.08 |
| Lymphocyte, µx10\textsuperscript{3}/µL           | 1.5 ± 0.4        | 1.4 ± 0.39       | 1.6 ± 0.4       | < 0.01 |
| Platelet, µx10\textsuperscript{3}/µL             | 358 ± 59         | 380 ± 44         | 304 ± 57        | < 0.01 |
| Target vessel, n (%)                             | LAD              | 21 (23.3)        | 12 (18.8)       | 9 (34.6) |
|                                                   | Cx               | 19 (21.1)        | 11 (17.2)       | 8 (30.8) |
|                                                   | RCA              | 50 (55.6)        | 41.6 (41.4)     | 9 (34.6) |
| Rentrop classification, n (%)                     | Rentrop 1        | 22 (24.4)        | 12 (18.8)       | 10 (38.8) |
|                                                   | Rentrop 2        | 35 (38.9)        | 23 (35.9)       | 12 (46.2) |
|                                                   | Rentrop 3        | 33 (36.7)        | 29 (45.3)       | 4 (15.4) |

Abbreviations: LVEF, left ventricular ejection fraction; MI, myocardial infarction; CABG, coronary artery by-pass grafting; CVA, cerebrovascular accident; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; CRP, C-reactive protein; RCA, right coronary artery; Cx, circumflex artery; LAD, left anterior descending artery

| Table 2. Comparison of pre- and post-PCI P-wave parameters of all cases |
|---------------------------------------------------------------|---------------|---------------|
| Pre-PCI                                                       | Post-PCI at 12th months | P value |
| Successful PCI group                                         |               |               |
| P\textsuperscript{max}, ms                                   | 56 ± 3.3      | 57.2 ± 4.5    | 0.02 |
| P\textsuperscript{min}, ms                                   | 114.8 ± 3.3   | 108.8 ± 3.3   | <0.01 |
| PWD, ms                                                      | 58.7 ± 6.1    | 51.4 ± 6.3    | <0.01 |
| unsuccessful PCI group                                       |               |               |
| P\textsuperscript{max}, ms                                   | 56.4 ± 2.2    | 56.7 ± 2.4    | 0.16 |
| P\textsuperscript{min}, ms                                   | 114.4 ± 2.2   | 114.2 ± 2.3   | 0.33 |
| PWD, ms                                                      | 56.7 ± 2.4    | 57.5 ± 4.7    | 0.33 |

Abbreviations: PCI, percutaneous coronary intervention; P\textsuperscript{max}, P-wave maximum time; P\textsuperscript{min}, P-wave minimum time; PWD, P wave dispersion
Table 3. Comparison of pre- and post-PCI electrocardiographic parameters based on the Rentrop classification

| Rentrop 1 | Pre-PCI | Post-PCI at 12th months | P value |
|----------|---------|------------------------|---------|
| P_{max}, ms | 55.1±3.5 | 57.6±5.3 | 0.05 |
| P_{min}, ms | 116.2±3.0 | 112.5±3.0 | <0.01 |
| PWD, ms | 60.2±6.6 | 55.7±2.2 | <0.01 |

| Rentrop 2 | Pre-PCI | Post-PCI at 12th months | P value |
|----------|---------|------------------------|---------|
| P_{max}, ms | 55.9±2.8 | 55.9±3.1 | 1.0 |
| P_{min}, ms | 114.6±2.8 | 110.7±4.0 | <0.01 |
| PWD, ms | 58.4±5.5 | 54.1±5.4 | <0.01 |

| Rentrop 3 | Pre-PCI | Post-PCI at 12th months | P value |
|----------|---------|------------------------|---------|
| P_{max}, ms | 57±2.8 | 58±3.7 | 0.02 |
| P_{min}, ms | 113.8±2.8 | 108.6±3.6 | <0.01 |
| PWD, ms | 56.7±5.5 | 51.1±6.6 | <0.01 |

Abbreviations: PCI, percutaneous coronary intervention; P_{max}, P-wave maximum time; P_{min}, P-wave minimum time; PWD, P wave dispersion

Discussion

Our study revealed that P wave duration and PWD were significantly reduced after revascularization with PCI in patients with CTO at 12th months follow-up. We assume that atrial conduction disturbance might be improved by CTO PCI revascularization, thereby possibly reducing atrial arrhythmias triggered by pro-arrhythmic effects of CTO.

The identification of atrial fibrosis in the heart failure experimental model at the beginning of the century and, consequently, causing the slowing of conduction and increased conduction heterogeneity, it was accepted that atrial structural remodeling contributed to the continuation of AF.11-13 Experimental and clinical studies have shown various AF risk factors, including heart failure, valvular heart disease, and endurance training.11-15

PWDs are simple and inexpensive measurements reflecting the regional heterogeneity of atrial repolarization. The PWD is an index that reflects the risk of AF.16 PWD changes have been studied in patients with acute myocardial infarction, chronic coronary syndrome, and angioplasty-induced myocardial ischemia. In a study of Dilaveris et al, PWD was found to be longer in cases with stable anginal episodes compared with those who did not have.17

The CTO of the coronary arteries is detected in 35-50% of cases with significant CAD undergoing diagnostic CAG.18 Remarkably, PCI has become a widely accepted treatment strategy for CTO in current practice.19 Studies found that improved left ventricular (LV) systolic function, less anginal symptoms, greater exercise capacity, decreased need for CABG, and, most significantly, longer survival rates had all been linked to successful PCI of CTO.20,21 The effect of revascularization on outcome in cases with LV systolic dysfunction has recently been answered by the results of the randomized Surgical Treatment for Ischemic Heart Failure(STICH) study.22 PCI has been reported to benefit for CTO cases by reducing ischemic symptoms and mortality owing to the improvement of myocardial function.23,24

The observations of our study showed that PWD was significantly reduced after revascularization of CTO. We consider that some mechanisms may be the underlying reasons for the improvement of atrial conduction.25 LV diastolic and/or systolic functions may be reduced in CTO patients due to prolonged conduction. An increase in left atrial pressure and diameter is expected to develop as a consequence of elevated LV end-diastolic pressure (LVEDP). Conduction abnormalities can occur in the atrial myocardium as a consequence of increased left atrial diameter and pressure. Improvement in atrial electrical conduction is expected as a result of a reduction in LVEDP after CTO recanalization.24 In our study, we observed that PWD was significantly reduced, which might mean an improvement in the progression of sinus impulses. In CTO conditions, a direct atrial wall ischemia can occur as a result of atrial fibrosis, which may be another explanation for the prolongation of PWD. As a result of fibrosis in the atrial wall, there may be no homogeneity in atrial conduction. P_{min} and PWD were significantly reduced in cases with CTO lesions after recanalization, and it may be due to the healing of atrial tissue as well as improvement of atrial conduction as noted above.

Even though successful CTO recanalization has been associated with better clinical benefits, the outcomes of patients with AF undergoing CTO PCI have not been investigated yet. The relationship between PWD and AF had been shown in a previous study.25 However, we did not show that CTO PCI directly reduced the risk of AF in our study; however, since the relationship between PWD and AF was well-known, we thought that a decrease in PWD might decrease the incidence of AF. Besides that, we found that P_{min} and PWD were significantly reduced after recanalization in patients with CTO regardless of vessel type.

Several limitations are evident in our study. The main limitation was retrospective design of the study. The sample size was also relatively small; hence, further prospective studies with larger cohorts may be needed to confirm the results. Although patients who developed AF following CTO PCI procedure were excluded, a 24-hours Holter monitoring was not performed to detect AF during long-term follow-up. Lastly, we measured the conduction times only with ECG and we did not perform electrophysiological study, which is the gold standard method that should be used to validate our results.

Conclusion

The present investigation has showed that P_{min} and PWD might be significantly reduced at 12th months following successful CTO recanalization by PCI.
Acknowledgements
None.

Competing interest
The authors state that they have no competing interests in the publication of this paper.

Ethical approval
The Local Ethic Committee examined and approved the study protocol (Decision number: 276).

Funding
None.

References
1. Weber UK, Osvald S, Huber M, Buser P, Skarvan K, Stulz P, et al. Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery: is there a need for pre-operative risk stratification? a prospective placebo-controlled study using low-dose sotalol. Eur Heart J. 1998;19(5):794-800. doi:10.1053/ehj.1997.0838
2. Okutucu S, Aytemir K, Oto A. P-wave dispersion: what we know till now? JRSM Cardiovasc Dis. 2016;5:20480041016639443. doi:10.1177/2048004116639443
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. doi:10.1161/01.cir.98.10.946
4. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133(5):484-492. doi:10.1161/circulationaha.115.018614
5. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961-972. doi:10.1056/NEJMoa0804626
6. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Osherov AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012;59(11):991-997. doi:10.1016/j.jacc.2011.12.007
7. Erdogan E, Akkaya M, Bacaksiz A, Tasal A, Sonmez O, Asoglu E, et al. Short-term effect of percutaneous recanalization of chronic total occlusions on PT dispersion and heart rate variability parameters. Med Sci Monit. 2013;19:696-702. doi:10.12659/msm.889511
8. Dilaveris PE, Andrikopoulos GK, Metaxas G, Richter DJ, Avgouropoulou CK, Androulakis AM, et al. Effects of ischemia on P wave dispersion and maximum P wave duration during spontaneous anginal episodes. Pacing Clin Electrophysiol. 1999;22(11):1640-1647. doi:10.1111/j.1540-8159.1999.tb0384x
9. Sianos G, Werner GS, Galassi AR, Papaflakis MI, Escaned J, Hildick-Smith D, et al. Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCCTO club. EuroIntervention. 2012;8(1):139-145. doi:10.4244/eijv8ia121
10. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985;5(3):587-592. doi:10.1016/s0735-1097(85)80380-6
11. Lau DH, Mackenzie L, Kelly DJ, Psaltsis PJ, Brooks AG, Worthington M, et al. Hypertension and atrial fibrillation: evidence of progressive atrial remodeling with electrostructural correlate in a conscious chronically instrumented ovine model. Heart Rhythm. 2010;7(9):1282-1290. doi:10.1016/j.hrthm.2010.05.010
12. Lau DH, Shipp NJ, Kelly DJ, Thanigaimani S, Neo M, Kuklik P, et al. Atrial arrhythmia in ageing spontaneously hypertensive rats: unraveling the substrate in hypertension and ageing. PLoS One. 2013;8(8):e72416. doi:10.1371/journal.pone.0072416
13. Medi C, Kalman JM, Spence SJ, Teh AW, Lee G, Bader I, et al. Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(12):1317-1324. doi:10.1111/j.1540-8167.2011.02125.x
14. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90-100. doi:10.1016/j.hrthm.2012.08.043
15. Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015;66(1):1-11. doi:10.1016/j.jacc.2015.04.058
16. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol. 2000;36(6):1749-1766. doi:10.1016/s0735-1097(00)00962-1
17. Dilaveris PE, Gialafos JE. Future concepts in P wave morphological analyses. Card Electrophysiol Rev. 2002;6(3):221-224. doi:10.1023/a:1016320807103
18. Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95(9):1088-1091. doi:10.1016/j.amjcard.2004.12.065
19. Ge JB. Current status of percutaneous coronary intervention of chronic total occlusion. J Zhejiang Univ Sci B. 2012;13(8):589-602. doi:10.1631/jzus.B1201009
20. Khan MF, Wendel CS, Thai HM, Movahed MR. Effects of percutaneous revascularization of chronic total occlusions on clinical outcomes: a meta-analysis comparing successful versus failed percutaneous intervention for chronic total occlusion. Catheter Cardiovasc Interv. 2013;82(1):95-107. doi:10.1002/ccd.24863
21. Olivari Z, Rubartelli P, Piscione F, Ettori F, Fontanelli A, Salemme L, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003;41(10):1672-1678. doi:10.1016/s0735-1097(03)00312-7
22. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left
ventricular dysfunction. N Engl J Med. 2011;364(17):1607-1616. doi:10.1056/NEJMoaj1100356

23. Olivari Z, Rubartelli P, Piscione F, Ettori F, Fontanelli A, Salemme L, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003;41(10):1672-1678. doi:10.1016/s0735-1097(03)00312-7

24. Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR, Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007;49(15):1611-1618. doi:10.1016/j.jacc.2006.12.040

25. Zhang X, Zeng W, Li Y, Hou D, Li X, Xu W. Evaluation of P wave dispersion and tissue Doppler imaging for predicting paroxysmal atrial fibrillation in patients with hypertension. Heart Surg Forum. 2018;21(1):E054-E058. doi:10.1532/hsf.1832